SCHEMBL3948745

SCHEMBL3948745

OC(c1ccncc1)C1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.39
CYP19A1 P11511 3/20 0.39
CYP17A1 P05093 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
DHODH Q02127 1/20 0.39
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
ROCK2 O75116 4/20 0.38
ROCK1 Q13464 4/20 0.38
KDM4E B2RXH2 2/20 0.38
CYP2D6 P10635 2/20 0.38
TSHR P16473 2/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.37
HSD17B10 Q99714 1/20 0.36
PKN2 Q16513 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22984539 0.90 DHODH (0.50) CYP19A1CYP11B2DHODHROCK2ROCK1
SCHEMBL23882954 0.90 DHODH (0.50) CYP19A1CYP11B2DHODHROCK2ROCK1
SCHEMBL3301921 0.86 SLC6A4 (0.46) CYP11B2SLC6A2SLC6A4SLC6A3ROCK2
SCHEMBL30020038 0.78 HPGD (0.42) CYP3A4SLC6A2SLC6A4SLC6A3KDM4E
SCHEMBL477699 0.76 CYP1A2 (0.56) CYP3A4KDM4ECYP2D6TSHRHTR2A
SCHEMBL19645377 0.76 CYP1A2 (0.56) CYP3A4KDM4ECYP2D6TSHRHTR2A
SCHEMBL8795521 0.75 SMN1; SMN2 (0.53) CYP3A4CYP19A1CYP17A1CYP11B2SLC6A2
SCHEMBL30896272 0.75 SMN1; SMN2 (0.53) CYP3A4CYP19A1CYP17A1CYP11B2SLC6A2
SCHEMBL5843905 0.73 SLC6A4 (0.38) CYP3A4CYP19A1CYP17A1CYP11B1CYP11B2
SCHEMBL13450376 0.73 DHODH (0.46) CYP3A4DHODHKDM4ECYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016007714-A1 PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2016-01-14 WO disclosed
EP-1703908-A4 ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO AMGEN INC (US) 2009-07-08 EP disclosed
US-7365075-B2 Aryl sulfonamide compounds and uses related thereto AMGEN INC. (US) 2008-04-29 US disclosed
EP-1703908-A1 ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO Amgen Inc. (US) 2006-09-27 EP disclosed
US-20050277649-A1 Aryl sulfonamide compounds and uses related thereto AMGEN SF, LLC (US) 2005-12-15 US disclosed
WO-2005063247-A1 ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO AMGEN INC. (US) 2005-07-14 WO disclosed
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US disclosed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 EP disclosed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 EP disclosed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof CYP2S1, IMPDH1, IDO1 CYP3A4 63/4885CYP19A1 180/4885CYP17A1 167/4885
US-20050277649-A1 Aryl sulfonamide compounds and uses related thereto SULT2A1, ARSA, SULT1A1 CYP3A4 90/4885CYP19A1 35/4885CYP17A1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.